On Friday, CeriBell got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 79.
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matched up against all other stocks.
Decades of market research reveals that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they begin their biggest price moves. See if CeriBell can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
While now is not an ideal time to buy shares, see if the stock manages to establish and enter a buying range in heavy trade.
The company reported 0% earnings growth last quarter, while sales growth came in at 40%. The company is expected to report its latest results on or around Nov. 12.
The company earns the No. 46 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Globus Medical and Pro-Dex are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
